Tag: Autism

  • Nicole Shanahan Is Just Getting Started

    Nicole Shanahan Is Just Getting Started

    [ad_1]

    A person familiar with the matter noted that Brin, unlike Shanahan, doesn’t appear to discuss their daughter’s autism diagnosis or treatment publicly. (He also hasn’t commented publicly on Shanahan’s campaign or post-divorce philanthropy.)

    In other words, two phenomenally wealthy ex-spouses are poised to become the respective faces of autism philanthropy and autism pseudoscience. This is potentially much more consequential than Shanahan’s candidacy, and the people involved in these worlds are already either deeply apprehensive or thrilled, depending on their perspective.

    “Other than Robert F. Kennedy Jr., I have never heard any candidate for major office speak with such clarity, candor, and courage about autism and chronic disease,” John Gilmore, the founder of the Autism Action Network, a group that blames vaccines and other environmental factors for autism, wrote recently.

    “Shanahan’s autism knowledge comes from her own lived experience,” he added. And then, in bold, he proclaimed, “Nicole Shanahan is one of us.”

    Shanahan has helped fund projects ranging from labs studying female fertility and reproductive longevity to Evolver, a Cate Blanchett-narrated “collective virtual reality experience which drops audiences deep inside the landscape of the body.” These days, though, her true passion appears to be for pseudoscience. This has positioned her as a useful messenger to communicate to the anti-vaccine movement that Kennedy is still with them, even as he’s occasionally and fitfully tried to downplay his long career in that world. Not just a powerful funder and backer, Shanahan is a symbol of his unwavering commitment to the cause.

    Many parents develop vaccine injury suspicions after their child starts to display symptoms of autism spectrum disorder or other developmental conditions; those suspicions can take them deep into a world of pseudoscience and distrust. In a 2023 interview with People that focused largely on her divorce, Shanahan described that process for herself.

    “I talk to two scientists a week, typically, whether they’re neurosurgeons or neurologists or mitochondrial experts,” she told the outlet. “I chat with a lot of other mothers of autistic children because I think mothers are some of the most well-educated and researched … They’re trying some of these autism interventions and they’re able to tell you with greater accuracy than any published medical paper what they’re seeing in their children.”

    Despite Kennedy’s and Shanahan’s concerns, though, vaccines don’t cause autism. A huge body of research and evidence, including a major decade-long Danish study of people who received MMR vaccines, published in 2019, has demonstrated that over and over and over. A second theory, that thimerosal, a preservative previously used in some childhood vaccines, causes autism has also been repeatedly debunked. (Thimerosal was never used in MMR vaccines, creating a clear logical issue for anti-vaccine activists who use that argument.) Yet another claim, that “too many” childhood vaccines at once can cause autism, has also been conclusively debunked.

    Suspicions like Shanahan’s have nonetheless led many parents to pursue life-changing actions, spending money on bogus treatments for their children and getting sucked into an anti-vaccine movement—of which Kennedy has been an integral part—that monetizes their pain and frustration.

    [ad_2]

    Source link

  • What neurodiversity means for psychiatrists and the people they help

    What neurodiversity means for psychiatrists and the people they help

    [ad_1]

    2RDCYB1 Kid with backpack with autism infinity rainbow symbol sign. World autism awareness day, autism rights movement, neurodiversity, autistic acceptance

    Jurgita Vaicikeviciene/Alamy

    As a child, I was frequently scolded for zoning out in class, interrupting conversations and losing just about everything I owned. It wasn’t until adulthood, when I was diagnosed with ADHD, that these “bad habits” began to make sense.

    The idea that my brain is wired differently is the foundation of neurodiversity, a relatively new framework for understanding neurodevelopmental conditions like ADHD and autism. “Neurodiversity reflects an awareness that, across humanity, we have many different ways of perceiving and relating to the world that reflect differences in our brain development and brain function,” says Geraldine Dawson at Duke University in North Carolina.

    Instead of viewing these differences as problems to be fixed, a neurodiverse approach aims to embrace them, she says.

    That seems clear enough. But the concept of neurodiversity has been a source of debate in recent years, particularly in terms of what it means for psychiatrists and neuroscientists, who have long thought in terms of neurodevelopmental “disorders”, and the people they are seeking to help.

    “Some people take it that the neurodiversity paradigm is against the medical paradigm,” says Anita Thapar, a psychiatrist at Cardiff University in the UK. “What I have argued in several papers is that both are useful for different purposes.”

    What is neurodiversity?

    To start from the beginning, the term “neurodiverse” was first coined in the late 1990s by sociologist Judy Singer, who used it when describing people with autism who had no intellectual impairments but struggled with relating to others or had repetitive behaviours.

    The idea was to view autism…

    [ad_2]

    Source link

  • Study suggests a promising new approach to understanding autism

    Study suggests a promising new approach to understanding autism

    [ad_1]

    Autism spectrum disorder has yet to be linked to a single cause, due to the wide range of its symptoms and severity. However, a study by University of Virginia researchers suggests a promising new approach to finding answers, one that could lead to advances in the study of other neurological diseases and disorders.

    Current approaches to autism research involve observing and understanding the disorder through the study of its behavioral consequences, using techniques like functional magnetic resonance imaging that map the brain’s responses to input and activity, but little work has been done to understand what’s causing those responses.

    However, researchers with UVA’s College and Graduate School of Arts & Sciences have been able to better understand the physiological differences between the brain structures of autistic and non-autistic individuals through the use of Diffusion MRI, a technique that measures molecular diffusion in biological tissue, to observe how water moves throughout the brain and interacts with cellular membranes. The approach has helped the UVA team develop mathematical models of brain microstructures that have helped identify structural differences in the brains of those with autism and those without.

    “It hasn’t been well understood what those differences might be,” said Benjamin Newman, a postdoctoral researcher with UVA’s Department of Psychology, recent graduate of UVA School of Medicine’s neuroscience graduate program and lead author of a paper published this month in PLOS: One. “This new approach looks at the neuronal differences contributing to the etiology of autism spectrum disorder.”

    Building on the work of Alan Hodgkin and Andrew Huxley, who won the 1963 Nobel Prize in Medicine for describing the electrochemical conductivity characteristics of neurons, Newman and his co-authors applied those concepts to understand how that conductivity differs in those with autism and those without, using the latest neuroimaging data and computational methodologies. The result is a first-of-its-kind approach to calculating the conductivity of neural axons and their capacity to carry information through the brain. The study also offers evidence that those microstructural differences are directly related to participants’ scores on the Social Communication Questionnaire, a common clinical tool for diagnosing autism.

    What we’re seeing is that there’s a difference in the diameter of the microstructural components in the brains of autistic people that can cause them to conduct electricity slower. It’s the structure that constrains how the function of the brain works.”

    Benjamin Newman, postdoctoral researcher with UVA’s Department of Psychology

    One of Newman’s co-authors, John Darrell Van Horn, a professor of psychology and data science at UVA, said, that so often we try to understand autism through a collection of behavioral patterns which might be unusual or seem different.

    “But understanding those behaviors can be a bit subjective, depending on who’s doing the observing,” Van Horn said. “We need greater fidelity in terms of the physiological metrics that we have so that we can better understand where those behaviors coming from. This is the first time this kind of metric has been applied in a clinical population, and it sheds some interesting light on the origins of ASD.”

    Van Horn said there’s been a lot of work done with functional magnetic resonance imaging, looking at blood oxygen related signal changes in autistic individuals, but this research, he said “Goes a little bit deeper.” 

    “It’s asking not if there’s a particular cognitive functional activation difference; it’s asking how the brain actually conducts information around itself through these dynamic networks,” Van Horn said. “And I think that we’ve been successful showing that there’s something that’s uniquely different about autistic-spectrum-disorder-diagnosed individuals relative to otherwise typically developing control subjects.”

    Newman and Van Horn, along with co-authors Jason Druzgal and Kevin Pelphrey from the UVA School of Medicine, are affiliated with the National Institute of Health’s Autism Center of Excellence (ACE), an initiative that supports large-scale multidisciplinary and multi-institutional studies on ASD with the aim of determining the disorder’s causes and potential treatments. 

    According to Pelphrey, a neuroscientist and expert on brain development and the study’s principal investigator, the overarching aim of the ACE project is to lead the way in developing a precision medicine approach to autism. 

    “This study provides the foundation for a biological target to measure treatment response and allows us to identify avenues for future treatments to be developed,” he said.

    Van Horn added that study may also have implications for the examination, diagnosis, and treatment of other neurological disorders like Parkinson’s and Alzheimer’s.

    “This is a new tool for measuring the properties of neurons which we are particularly excited about. We are still exploring what we might be able to detect with it,” Van Horn said.

    Source:

    Journal reference:

    Newman, B. T., et al. (2024) Conduction velocity, G-ratio, and extracellular water as microstructural characteristics of autism spectrum disorder. PLOS ONE. doi.org/10.1371/journal.pone.0301964.

    [ad_2]

    Source link

  • Environmental stressors linked to fetal brain development challenges

    Environmental stressors linked to fetal brain development challenges

    [ad_1]

    In a recent review article published in the journal Antioxidants, researchers explored how environmental factors impact the brain development of fetuses and neonates, emphasizing inflammation and oxidation stress as common denominators across various stressors.

    Their conclusions highlight the critical role of healthy intrauterine environments for promoting fetal brain development and stress the importance of interventions that aim to reduce modifiable stress factors during pregnancy.

    Review: Impact of Maternal Environment and Inflammation on Fetal Neurodevelopment. Image Credit: Sebastian Kaulitzki / ShutterstockReview: Impact of Maternal Environment and Inflammation on Fetal Neurodevelopment. Image Credit: Sebastian Kaulitzki / Shutterstock

    Background

    The development of the human brain, which commences during the second to third week of gestation and continues through childhood, is influenced by a combination of genetic, epigenetic, and environmental factors.

    Key developmental milestones occur during specific gestational periods, such as cellular migration in the neocortex and extensive neurogenesis between the eighth and eighteenth weeks.

    Maternal environmental exposures during the prenatal and antenatal periods can impact intrauterine development and the short—and long-term health of the offspring, potentially raising the risks of developing non-communicable diseases in adulthood.

    These exposures can epigenetically modify placental and fetal phenotypes, affecting organ structure, metabolism, and physiology. However, understanding the precise molecular mechanisms linking external factors to neurodevelopmental alterations remains challenging.

    In this review, researchers aimed to explore the effects of various maternal environmental exposures, including nutrition, lifestyle, stress, and pollution, on fetal brain development and neonatal neurodevelopment-related outcomes, drawing from a comprehensive literature search that encompassed human and animal studies published within the last 15 years.

    External stimuli, through inflammation and reduced micronutrient supply, impact on fetal neurodevelopment. SES: socioeconomic status.External stimuli, through inflammation and reduced micronutrient supply, impact on fetal neurodevelopment. SES: socioeconomic status.

    Maternal environmental exposures

    Maternal nutrition plays a crucial role in fetal neurodevelopment, with evidence suggesting that both insufficient and unhealthy dietary patterns during pregnancy can affect fetal brain development.

    For example, the Mediterranean diet, characterized by nutrient-rich foods, has been associated with positive neurodevelopmental outcomes in offspring.

    However, deficiencies in micronutrients like docosahexaenoic acid (DHA), folate, and iodine and excessive intake of macronutrients have been linked to adverse neurodevelopmental effects.

    The Western diet, in particular, is known to be high in macronutrients but poor in micronutrients. Affordable but low-quality foods characterize it. Mouse models suggest that pow-protein diets may also be associated with neurodevelopmental delays.

    Alterations in maternal gut microbiota during pregnancy have been linked to worse behavioral outcomes in offspring, potentially mediated through inflammation and metabolic endotoxemia.

    Maternal obesity and a high-fat diet have also been implicated, with animal models and epidemiological studies suggesting associations with cognitive deficits, attention deficit hyperactivity disorder (ADHD), autism, and psychoses in offspring.

    Additionally, maternal depression, anxiety, and stress can lead to disturbed fetal neurodevelopment, potentially resulting in altered brain structure and function, as evidenced by investigations using human and animal models.

    Smoking and alcohol consumption during pregnancy have well-documented detrimental effects on fetal neurodevelopment, including increased risks of ADHD, autism, schizophrenia, and behavioral issues.

    Exposure to air pollution, mainly particulate matter, and polycyclic aromatic hydrocarbons, has been linked to neurodevelopmental disorders in offspring, with oxidative stress and inflammatory responses implicated as underlying mechanisms.

    Socioeconomic status also plays a role, with disadvantaged conditions associated with adverse pregnancy outcomes and poorer neurodevelopmental outcomes in children.

    Underlying mechanisms

    Numerous studies have linked pathological pregnancy conditions like fetal growth restriction (FGR) and preterm birth (PTB) with neurodevelopmental issues in offspring. Two main mechanisms are implicated: altered fetal nutrient supply and intrauterine inflammation involving placental factors.

    FGR, often due to placental dysfunction, leads to chronic fetal hypoxia and undernutrition, impacting fetal brain development despite adaptive responses like brain sparing.

    PTB, often linked to maternal inflammation or infection, presents various neurodevelopmental challenges, including disruptions in axonal and neuronal development and brain abnormalities like cerebral palsy.

    Inflammation during pregnancy, exacerbated by factors like obesity, stress, and environmental pollutants, influences insulin and neurotransmitter signaling, affecting synaptic plasticity and neurotrophic factor expression.

    The activation of maternal immune systems contributes to mitochondrial dysfunction and oxidative stress, perpetuating a cycle of oxidative stress and inflammation that disrupts fetal brain development.

    These conditions and exposure to chemicals can compromise the blood-brain barrier and lead to additional impairments in fetal brain development.

    Overall, maternal health conditions and external factors collectively contribute to increased maternal inflammation, which impacts fetal neurodevelopment and potentially leads to long-term neurological consequences in offspring.

    Conclusions

    The review emphasizes how external factors during pregnancy affect fetal growth and brain development, impacting long-term neurodevelopment.

    Conditions like PTB and FGR alter brain morphometry, often due to inflammation and changes in nutrient supply. Evidence suggests they are influenced by maternal health and environmental factors like air pollution and stress.

    Understanding and addressing these modifiable risk factors is crucial for improving both individual and public health outcomes. This highlights the importance of preventive measures and further longitudinal research.

    Journal reference:

    • Impacts of maternal environment and inflammation on fetal neurodevelopment. Lubrano, C., Parisi, F., Cetin, I. Antioxidants (2024). DOI: 10.3390/antiox13040453, https://www.mdpi.com/2076-3921/13/4/453

    [ad_2]

    Source link

  • NJHF awards $135K to Kessler Foundation scientists for pilot research projects

    NJHF awards $135K to Kessler Foundation scientists for pilot research projects

    [ad_1]

    This year, New Jersey Health Foundation (NJHF) granted $135,000 in awards to three Kessler Foundation scientists to support pilot research projects that exhibit promising potential. Foundation researchers will conduct studies that expand research in web-based job interview training for youth on the autism spectrum, upper extremity robotics for individuals with chronic spinal cord injury, and adding three additional assessment items to the Kessler Foundation Neglect Assessment Process (KF-NAP®).

    Ghaith J. Androwis, PhD, senior research scientist in the Center for Mobility and Rehabilitation Engineering Research and director of the Center’s Rehabilitation Robotics and Research Laboratory at Kessler Foundation, received a $50,000 one-year grant for his study “Wearable Robotic Orthosis Combined with Visual/Haptic Feedback to Improve Upper Extremity Function and ADL in Persons with Chronic SCI.”

    Among an estimated 17,700 new traumatic SCI cases reported each year in the United States, about half of those injuries are accompanied by arm and hand movement disabilities. While numerous rehabilitation technologies, including wearable robotics, facilitate hand and arm movement for daily functioning, few undergo systematic evaluation to assess their effectiveness and therapeutic value in improving these capabilities.

    “Our study will examine the effect of the wearable upper extremity robotic MyoPro orthotic on improving and recovering arm and hand movement function and activity of daily living in persons with chronic SCI,” said Dr. Androwis. “In addition, the study will evaluate whether providing visual/haptic feedback while the patients are assisted with the MyoPro orthotic could improve therapeutic effects of the intervention.

    “The findings from the study would support the use of integrated technologies – robotic assistance + real-time feedback – in promoting upper extremity movement function and positively impact health and welfare of people with SCI,” he explained.

    Peii (Peggy) Chen, senior research scientist in the Center for Stroke Rehabilitation Research and director of the Center’s Spatial Attention, Awareness, and Ability Laboratory, received a one-year $50,000 grant for her study “Ecological Assessment for Chronic Spatial Neglect.” Chronic spatial neglect is under-represented in research and under-treated clinically, often because chronic symptoms are often undetected by currently available standardized assessments carried out in inpatient settings.

    We developed three additional assessment items (reading, pill organization, and way finding) to add to the 10-item KF-NAP,” said Dr. Chen. The widely used KF-NAP uniquely measures spatial neglect during activities of daily living by assessing functional difficulties that are not captured by Functional Independence Measure (FIM™) and Barthel Index.


    We’ll use study results to secure federal grants for exploring the feasibility of using KF-NAP-13 in outpatient and home settings, and use it as the primary outcome measure in future clinical trials evaluating long-term functional outcomes among stroke survivors.”


    Dr. Peii (Peggy) Chen, senior research scientist in the Center for Stroke Rehabilitation Research and director of the Center’s Spatial Attention, Awareness, and Ability Laboratory

    Helen Genova, PhD, associate director in the Center for Autism Research and director of the Center’s Social Cognition and Neuroscience Laboratory received a one-year, $35,000 grant for her study named “Exploring the Implementation of a Job Interview Training Program for Autistic Youth in a Real-World Setting.”

    “Because autistic youth face extremely high rates of unemployment, it is critical that interventions are developed to improve employment outcomes in this vulnerable population. One obstacle to employment is the job interview, which can be challenging for individuals on the spectrum,” explained Dr. Genova.

    “Our study will evaluate the effectiveness of an innovative web-based job interview training tool, Kessler Foundation Strength Identification and Expression (KF-STRIDE®),” said Dr. Genova. “This tool teaches autistic youth how to speak about their unique employable strengths,” she added.

    KF-STRIDE has been used only in lab-based settings, which limits its potential usefulness to the greater community. “Our study will evaluate KF-STRIDE in a real-world setting: a community organization that offers employment training to autistic youth,” she added. “We’ll assess KF-STRIDE’s impact on job interview skills and employment outcomes, pre- and post-intervention. Additionally, we’ll gather qualitative feedback from teachers and students in the community to gauge its real-world usability and effectiveness,” explained Dr. Genova.

    [ad_2]

    Source link

  • Study finds dysfunction of key brain systems in people with psychosis

    Study finds dysfunction of key brain systems in people with psychosis

    [ad_1]

    Inside the brains of people with psychosis, two key systems are malfunctioning: a “filter” that directs attention toward important external events and internal thoughts, and a “predictor” composed of pathways that anticipate rewards.

    Dysfunction of these systems makes it difficult to know what’s real, manifesting as hallucinations and delusions.

    The findings come from a Stanford Medicine-led study, publishing April 11 in Molecular Psychiatry, that used brain scan data from children, teens and young adults with psychosis. The results confirm an existing theory of how breaks with reality occur.

    This work provides a good model for understanding the development and progression of schizophrenia, which is a challenging problem.”


    Kaustubh Supekar, PhD, lead author, clinical associate professor of psychiatry and behavioral sciences

    The findings, observed in individuals with a rare genetic disease called 22q11.2 deletion syndrome who experience psychosis as well as in those with psychosis of unknown origin, advance scientists’ understanding of the underlying brain mechanisms and theoretical frameworks related to psychosis.

    During psychosis, patients experience hallucinations, such as hearing voices, and hold delusional beliefs, such as thinking that people who are not real exist. Psychosis can occur on its own and is a hallmark of certain serious mental illnesses, including bipolar disorder and schizophrenia. Schizophrenia is also characterized by social withdrawal, disorganized thinking and speech, and a reduction in energy and motivation.

    It is challenging to study how schizophrenia begins in the brain. The condition usually emerges in teens or young adults, most of whom soon begin taking antipsychotic medications to ease their symptoms. When researchers analyze brain scans from people with established schizophrenia, they cannot distinguish the effects of the disease from the effects of the medications. They also do not know how schizophrenia changes the brain as the disease progresses.

    To get an early view of the disease process, the Stanford Medicine team studied young people aged 6 to 39 with 22q11.2 deletion syndrome, a genetic condition with a 30% risk for psychosis, schizophrenia or both.

    Brain function in 22q11.2 patients who have psychosis is similar to that in people with psychosis of unknown origin, they found. And these brain patterns matched what the researchers had previously theorized was generating psychosis symptoms.

    “The brain patterns we identified support our theoretical models of how cognitive control systems malfunction in psychosis,” said senior study author Vinod Menon, PhD, the Rachael L. and Walter F. Nichols, MD, Professor; a professor of psychiatry and behavioral sciences; and director of the Stanford Cognitive and Systems Neuroscience Laboratory.

    Thoughts that are not linked to reality can capture the brain’s cognitive control networks, he said. “This process derails the normal functioning of cognitive control, allowing intrusive thoughts to dominate, culminating in symptoms we recognize as psychosis.”

    Cerebral sorting

    Normally, the brain’s cognitive filtering system -; aka the salience network -; works behind the scenes to selectively direct our attention to important internal thoughts and external events. With its help, we can dismiss irrational thoughts and unimportant events and focus on what’s real and meaningful to us, such as paying attention to traffic so we avoid a collision.

    The ventral striatum, a small brain region, and associated brain pathways driven by dopamine, play an important role in predicting what will be rewarding or important.

    For the study, the researchers assembled as much functional MRI brain-scan data as possible from young people with 22q11.2 deletion syndrome, totaling 101 individuals scanned at three different universities. (The study also included brain scans from several comparison groups without 22q11.2 deletion syndrome: 120 people with early idiopathic psychosis, 101 people with autism, 123 with attention deficit/hyperactivity disorder and 411 healthy controls.)

    The genetic condition, characterized by deletion of part of the 22nd chromosome, affects 1 in every 2,000 to 4,000 people. In addition to the 30% risk of schizophrenia or psychosis, people with the syndrome can also have autism or attention deficit hyperactivity disorder, which is why these conditions were included in the comparison groups.

    The researchers used a type of machine learning algorithm called a spatiotemporal deep neural network to characterize patterns of brain function in all patients with 22q11.2 deletion syndrome compared with healthy subjects. With a cohort of patients whose brains were scanned at the University of California, Los Angeles, they developed an algorithmic model that distinguished brain scans from people with 22q11.2 deletion syndrome versus those without it. The model predicted the syndrome with greater than 94% accuracy. They validated the model in additional groups of people with or without the genetic syndrome who had received brain scans at UC Davis and Pontificia Universidad Católica de Chile, showing that in these independent groups, the model sorted brain scans with 84% to 90% accuracy.

    The researchers then used the model to investigate which brain features play the biggest role in psychosis. Prior studies of psychosis had not given consistent results, likely because their sample sizes were too small.

    Comparing brain scans from 22q11.2 deletion syndrome patients who had and did not have psychosis, the researchers showed that the brain areas contributing most to psychosis are the anterior insula (a key part of the salience network or “filter”) and the ventral striatum (the “reward predictor”); this was true for different cohorts of patients.

    In comparing the brain features of people with 22q11.2 deletion syndrome and psychosis against people with psychosis of unknown origin, the model found significant overlap, indicating that these brain features are characteristic of psychosis in general.

    A second mathematical model, trained to distinguish all subjects with 22q11.2 deletion syndrome and psychosis from those who have the genetic syndrome but without psychosis, selected brain scans from people with idiopathic psychosis with 77.5% accuracy, again supporting the idea that the brain’s filtering and predicting centers are key to psychosis.

    Furthermore, this model was specific to psychosis: It could not classify people with idiopathic autism or ADHD.

    “It was quite exciting to trace our steps back to our initial question -; ‘What are the dysfunctional brain systems in schizophrenia?’ -; and to discover similar patterns in this context,” Menon said. “At the neural level, the characteristics differentiating individuals with psychosis in 22q11.2 deletion syndrome are mirroring the pathways we’ve pinpointed in schizophrenia. This parallel reinforces our understanding of psychosis as a condition with identifiable and consistent brain signatures.” However, these brain signatures were not seen in people with the genetic syndrome but no psychosis, holding clues to future directions for research, he added.

    Applications for treatment or prevention

    In addition to supporting the scientists’ theory about how psychosis occurs, the findings have implications for understanding the condition -; and possibly preventing it.

    “One of my goals is to prevent or delay development of schizophrenia,” Supekar said. The fact that the new findings are consistent with the team’s prior research on which brain centers contribute most to schizophrenia in adults suggests there may be a way to prevent it, he said. “In schizophrenia, by the time of diagnosis, a lot of damage has already occurred in the brain, and it can be very difficult to change the course of the disease.”

    “What we saw is that, early on, functional interactions among brain regions within the same brain systems are abnormal,” he added. “The abnormalities do not start when you are in your 20s; they are evident even when you are 7 or 8.”

    The researchers plan to use existing treatments, such as transcranial magnetic stimulation or focused ultrasound, targeted at these brain centers in young people at risk of psychosis, such as those with 22q11.2 deletion syndrome or with two parents who have schizophrenia, to see if they prevent or delay the onset of the condition or lessen symptoms once they appear.

    The results also suggest that using functional MRI to monitor brain activity at the key centers could help scientists investigate how existing antipsychotic medications are working.

    Although it’s still puzzling why someone becomes untethered from reality -; given how risky it seems for one’s well-being -; the “how” is now understandable, Supekar said. “From a mechanistic point of view, it makes sense,” he said.

    “Our discoveries underscore the importance of approaching people with psychosis with compassion,” Menon said, adding that his team hopes their work not only advances scientific understanding but also inspires a cultural shift toward empathy and support for those experiencing psychosis.

    “I recently had the privilege of engaging with individuals from our department’s early psychosis treatment group,” he said. “Their message was a clear and powerful: ‘We share more similarities than differences. Like anyone, we experience our own highs and lows.’ Their words were a heartfelt appeal for greater empathy and understanding toward those living with this condition. It was a call to view psychosis through a lens of empathy and solidarity.”

    Researchers contributed to the study from UCLA, Clinica Alemana Universidad del Desarrollo, Pontificia Universidad Católica de Chile, the University of Oxford and UC Davis.

    The study was funded by the Stanford Maternal and Child Health Research Institute’s Uytengsu-Hamilton 22q11 Neuropsychiatry Research Program, FONDEYCT (the National Fund for Scientific and Technological Development of the government of Chile), ANID-Chile (the Chilean National Agency for Research and Development) and the U.S. National Institutes of Health (grants AG072114, MH121069, MH085953 and MH101779).

    Source:

    Journal reference:

    Supekar, K., et al. (2024). Robust and replicable functional brain signatures of 22q11.2 deletion syndrome and associated psychosis: a deep neural network-based multi-cohort study. Molecular Psychiatry. doi.org/10.1038/s41380-024-02495-8.

    [ad_2]

    Source link

  • Pain reliever use in pregnancy shows no link to child neurodevelopmental disorders, study finds

    Pain reliever use in pregnancy shows no link to child neurodevelopmental disorders, study finds

    [ad_1]

    In a recent study published in the Journal of American Medical Association (JAMA), researchers assessed the association between acetaminophen use in pregnancy and the risk of intellectual disability, autism, and attention-deficit/hyperactivity disorder (ADHD) in children.

    Acetaminophen is commonly used for pain and fever management during pregnancy. However, the European Medicines Agency and the United States (US) Food and Drug Administration consider that its use might pose a minimal risk in pregnancy. Further, a 2021 consensus statement from international clinicians and scientists recommended that pregnant individuals may forgo acetaminophen unless medically indicated due to the potential risk of developmental disorders.

    Study: Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual Disability. Image Credit: luchschenF / ShutterstockStudy: Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual Disability. Image Credit: luchschenF / Shutterstock

    About the study

    In the present study, researchers investigated the use of acetaminophen in pregnancy and the risk of intellectual disability, ADHD, and autism in children. They included singleton children born in Sweden between July 1995 and December 2019. Unique identifiers assigned to residents at birth/emigration were used to link children and parents. Children were excluded if data on their parent’s birth country, age, household income/education, and region of residence were lacking.

    Acetaminophen usage during pregnancy was identified from the Medical Birth Register. Information on early drug exposure was prospectively collected at the first antenatal visit, around 8–10 gestational weeks, during which midwives conducted examinations/interviews and recorded the use of prescription or over-the-counter medications. Later, the physician and midwife documented the use of medications.

    From July 2005, the Medical Birth Register was supplemented with data from the Prescribed Drug Register, covering all prescription dispensations. The primary exposure was the ever-use of acetaminophen in pregnancy, ascertained from the Medical Birth and Prescribed Drug registers. A secondary exposure was the dose for a subsample with Prescribed Drug Register coverage.

    The average daily dose of acetaminophen was estimated for each pregnancy. Diagnoses of intellectual disability, ADHD, and autism, identified from the National Patient Register, were the primary outcomes. Children were followed up until neurodevelopmental disorder diagnosis, emigration, death, or December 31, 2021. Cox proportional hazard models were used to estimate hazard ratios and 95% confidence intervals, accounting for the clustering of siblings by family.

    Models were adjusted for covariates and the use of the following analgesics: aspirin, antimigraine medicines, non-aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), and opioids. Differences in absolute risk at 10 years were computed. Further, a sibling analysis was performed to account for unobserved environmental and genetic confounders shared between siblings, adjusted for all putative confounders.

    Findings

    Overall, the study included over 2.48 million children, of which 7.49% were exposed to acetaminophen in pregnancy. Drug exposure was more prevalent among children born to those with a higher body mass index (BMI) in early pregnancy, lower socioeconomic position, diagnoses of psychiatric conditions and neurodevelopmental disorders, and those who smoked during pregnancy.

    During a median of 13.4 years of follow-up, 188,929 children had a diagnosis of at least one neurodevelopmental disorder. In total, 146,386 children had ADHD, 68,584 had autism, and 24,554 had intellectual disability. The median age at the diagnosis of autism, ADHD, and intellectual disability was 11.6, 12.2, and 8.2, respectively. Children exposed to acetaminophen had a slightly higher risk of ADHD, autism, and intellectual disability than those who were unexposed.

    Differences in absolute risk at 10 years were slight. In models with sibling control, acetaminophen exposure was not associated with the risk of neurodevelopmental disorders. The magnitude of association between neurodevelopmental disorders and acetaminophen was similar to or lower than that for aspirin, opioids, antimigraine medications, and non-aspirin NSAIDs.

    Of note, aspirin was inversely associated with neurodevelopmental disorders in sibling analyses, while there was a null association between antimigraine medicines, opioids, and non-aspirin NSAIDs and neurodevelopmental disorders. There was a dose-response association in partially adjusted models, which attenuated upon covariate adjustment and diminished in the sibling analysis.

    Conclusions

    Taken together, sibling control analyses revealed no associations between the use of acetaminophen in pregnancy and children’s risk of ADHD, intellectual disability, and autism. This suggested that the small, increased risk of these disorders associated with acetaminophen use in models without sibling control might be attributable to unmeasured confounding.

    While a dose-response association pattern was observed, it was attenuated with increasing covariate control and nullified upon sibling control. Although acetaminophen was not associated with increased risk even with the highest dose, the researchers caution against interpreting it as a benchmark for safety.

    [ad_2]

    Source link

  • Researchers elucidate how gene mutation mechanism causes autism

    Researchers elucidate how gene mutation mechanism causes autism

    [ad_1]

    Researchers show how mutations of gene transcription and chromatin regulation-related genes cause autism.

    The loss-of-function mutation of KMT2C, a gene involved in histone modification, leads to the development of autism and other neurodevelopmental deficits. However, the precise mechanism of the disease progression is still unknown. Now, researchers from Japan have developed an animal model and elucidated the mechanism by which mutation in genes involved in chromatin modification causes autism. They have also discovered a drug that can be used in the treatment of autism.

    Autism spectrum disorder (ASD) encompasses neurodevelopmental conditions where patients display repetitive behavior and impaired sociality. Genetic factors have been shown to influence the development of ASD. Additionally, recent studies have shown that the genes involved in chromatin modification and gene transcription are involved in the pathogenesis of ASD. Among the many genes implicated in this process, the gene KMT2C (lysine methyltransferase 2c), which codes for a catalytic unit of H3K4 (histone H3 lysine 4) methyltransferase complex, has been identified to be associated with the development of autism and other neurodevelopmental disorders. Previous studies have shown that haploinsufficiency (a condition where, of the two copies of the gene, only one remains functional) of KMT2C is a risk factor for ASD and other neurodevelopmental disorders. However, the molecular mechanism through which the loss-of-function mutation in KMT2C leads to these conditions remains unclear.

    To address this knowledge gap, researchers from Juntendo University, RIKEN, and the University of Tokyo in Japan aimed to provide answers to these questions in a benchmark study published in the journal Molecular Psychiatry on 26 March 2024. The research team included Professor Tadafumi Kato from the Department of Psychiatry and Behavioral Science at Juntendo University Graduate School of Medicine, Dr. Takumi Nakamura and Dr. Atsushi Takata from the RIKEN Center for Brain Science, and Professor Takashi Tsuboi from Graduate School of Arts and Sciences, The University of Tokyo.

    To get to the bottom of KMT2C‘s role in ASD pathogenesis, the team developed and analyzed genetically engineered strain mice (Kmt2c+/fs) having a frameshift mutation that models the KMT2C haploinsufficiency. They then performed various behavioral analyses, in which they observed that the mutant mice exhibited lower sociality, inflexibility, auditory hypersensitivity, and cognitive impairments, which are all ASD-related symptoms.

    Next, they performed transcriptomic and epigenetic profiling to understand the basis of the molecular changes observed in the mutant mice. What they discovered was remarkable: the genes associated with increased ASD risk showed higher expression in these mutant mice.

    This was somewhat unexpected. KMT2C mediates H3K4 methylation, which is thought to activate gene expression, and thereby KMT2C haploinsufficiency was expected to cause reduced expression of target genes.”


    Dr. Atsushi Takata, RIKEN Center for Brain Science

    To gain mechanistic insights into their finding, the researchers carried out chromatin immunoprecipitation, a technique to determine the location on the DNA where the protein interacts with it. They found an overlap between KMT2C and the differentially expressed genes exhibiting reduced expression, suggesting that KMT2C haploinsufficiency leads to ASD-related transcriptomic changes through an indirect effect on gene expression.

    Further, to identify the cell types that contribute more to the pathological changes seen in the mutant mice, the researchers performed single-cell RNA sequencing of newborn mice brains. They observed that the altered genes associated with ASD risk were predominant in undifferentiated radial glial cells. However, a gross change in the cell composition was not observed, implying that the transcriptomic dysregulation does not severely impact cell fate.

    Finally, the researchers tested the effects of vafidemstat, a brain penetrant inhibitor of LSD1 (lysine-specific histone demethylase 1A), that could ameliorate histone methylation abnormalities. They found that vafidemstat improved the social deficits in the mutant mice and had an exceptional rescuing effect by changing the expression levels of the differentially expressed genes to their normal expression level. This finding showed that vafidemstat is a valid drug for mutant mice and can potentially help restore the normal transcriptomic state.

    What sets this discovery apart is that it challenges the commonly held belief that ASD disability may not be cured and demonstrates the efficacy of vafidemstat in improving ASD-like phenotypes. The results open doors to future research to strengthen the foundation for the pharmacologic treatment of ASD and other neurodevelopmental disorders. Prof. Kato concludes, “Our research shows that drugs similar to vafidemstat may be generalizable to multiple categories of psychiatric disorders.”

    Source:

    Journal reference:

    Nakamura, T., et al. (2024). Transcriptomic dysregulation and autistic-like behaviors in Kmt2c haploinsufficient mice rescued by an LSD1 inhibitor. Molecular Psychiatry. doi.org/10.1038/s41380-024-02479-8.

    [ad_2]

    Source link

  • Cannabis use in pregnancy may raise children’s risk of ADHD and autism

    Cannabis use in pregnancy may raise children’s risk of ADHD and autism

    [ad_1]

    A study of more than 220,000 people found that cannabis use during pregnancy was associated with their children having roughly twice the risk of ADHD, autism and intellectual disability

    [ad_2]

    Source link

  • SRF announces grant to support research on SynGAP-Related Disorder in adults

    SRF announces grant to support research on SynGAP-Related Disorder in adults

    [ad_1]

    The SynGAP Research Fund 501(c) today announced a grant to Dr. Danielle Andrade, Dr. Miles Thompson, Dr. Ryan Yuen, Dr. Rogier Kerssebook, and Dr. Anatoljevna Anna Kattentidt to support research on SynGAP-Related Disorder (SRD) in adults. SRD is a rare neurodevelopmental disorder that causes severe intractable epilepsy, and intellectual disability, and is one of the leading genetic causes of autism. 

    Dr. Andrade’s team recently published the only research on SRD in adults in Neurology Genetics, Rong 2023 which SRF was instrumental in encouraging and supporting via recruitment. See Dr. Andrade’s readout on this work at the 2022 SRF SYNGAP1 Conference here. The grant SRF is announcing today will build on that groundbreaking work. 

    Dr. Andrade, MD, the principal investigator for this work says “This research holds deep significance not just for the adults in this study but also for children affected by SYNGAP1. As children become adults, investigating the outcomes of SYNGAP1 is pivotal in empowering families and clinicians alike, equipping them to screen for, diagnose, and manage manifestations seen in adults. Also, findings of this study will be important to guide precision therapies as well as evaluate their efficacy.”

    Michael Graglia, Managing Director of SRF, and father to a child with SRD says “Dr. Andrade is the world’s leading expert in adults with DEEs, the SYNGAP1 community is very fortunate to have her attention focused on our disease. She and her colleagues are world-class.”

    Dr. Marta Dahiya, MD, SRF’s Head of Clinical and mother to an adult with SRD says, “While many patients today are not yet adults, they will all become adults and this research will inform and support their care and created the opportunity for adult patients to be included in therapeutic studies. Every family should be thrilled about this work.”

    It is exciting to see this transatlantic cooperation where the large number of adults with SYNGAP1 Related Disorders in the Netherlands are able to be studied and included in this essential work.”


    Katrien Deckers, head of SRF-Europe 

    How to sign up

    Families with a loved one with SYNGAP1 Related Disorder age 16 or older can join the accessible online study by emailing [email protected], more information is available in the study flyer

    About the project

    The primary goal is to comprehensively understand the adult phenotypes and natural history of SRD patients, as well as the differences between those with and without epilepsy, in order to promote optimal care among adult patients. 

    They will investigate the presence of seizures and their severity, movement abnormalities, adaptive skills, behavior, gastrointestinal symptoms, sleep difficulties, and comorbidities among patients at our Adult Genetic Epilepsy (AGE) clinic in Canada, at the adult SYNGAP1 clinic in the Netherlands and externally through patient organizations such as the SynGAP Research Fund.

    They will also determine the genotype/phenotype correlations between SYNGAP1 patients with and without epilepsy. This will be achieved via WGS sequencing to search for rare variants with large effect size that influences the phenotype, and the contribution of common variants to individual features of the phenotype, through calculating the polygenic risk score (PRS) for different comorbidities. This research will provide valuable insight into the unique experiences and clinical outcomes of adult patients with SRF while promoting dialogue on the importance of precise and timely diagnosis and treatment of adult patients.

    About the team

    Dr. Danielle Andrade, MD, MSc, FRCPC, is the Medical Director of the Epilepsy Program at University Health Network and founder and Director of Krembil Neuroscience Institute Adult Genetic Epilepsy (AGE) Program. Dr. Miles Thompson, Ph.D., GCGCVI Scientific Associate, is with Krembil Research Institute, Toronto Western Hospital, and University Health Network. Dr. Ryan Yuen, Ph.D. is the Senior Scientist, Genetics & Genome Biology Program, at The Hospital for Sick Children – Toronto, Canada. Dr. Rogier Kerssebook, MD, Ph.D. is a Consultant in Clinical Genetics, at Erasmus Medical Centre, Rotterdam, The Netherlands. Dr. Anatoljevna Anna Kattentidt, MD, is a Clinical Geneticist and Physician, at Erasmus Medical Center, Rotterdam, The Netherlands. 

    University Health Network, Toronto, Canada – https://www.uhn.ca

    The Hospital for Sick Children, Toronto, Canada – https://www.sickkids.ca 

    Erasmus Medical Centre, Rotterdam, the Netherlands – https://www.erasmusmc.nl/nl-nl/ 

    About SYNGAP1-related intellectual disability (SRD)

    SYNGAP1-related intellectual disability (US ICD-10 F78.A1 / Global ICD-11 LD90.Y) is a rare genetic disorder caused by variants on the SYNGAP1 gene that reduce SynGAP protein levels. This protein acts as a regulator in the synapses (where neurons communicate with each other). When SynGAP protein levels are too low, we see an increase in excitability in the synapses making it difficult for neurons to communicate effectively. This leads to many neurological issues seen in SynGAP patients.

    Symptoms of SYNGAP1 include intellectual disability; epilepsy; hypotonia (low muscle tone); gross and fine motor skill delays; autism spectrum disorder; gastro-intestinal issues; sleep and behavior disorders and visual abnormalities. 

    [ad_2]

    Source link